Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.
Gulati S, Hsu CY, Shah S, Shah PK, Zon R, Alsamarai S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshow DB, Egan PC, Fein J, Flora DB, Friese CR, Fromowitz A, Griffiths EA, Hwang C, Jani C, Joshi M, Khan H, Klein EJ, Heater NK, Koshkin VS, Kwon DH, Labaki C, Latif T, McKay RR, Nagaraj G, Nakasone ES, Nonato T, Polimera HV, Puc M, Razavi P, Ruiz-Garcia E, Saliby RM, Shastri A, Singh SRK, Tagalakis V, Vilar-Compte D, Weissmann LB, Wilkins CR, Wise-Draper TM, Wotman MT, Yoon JJ, Mishra S, Grivas P, Shyr Y, Warner JL, Connors JM, Shah DP, Rosovsky RP; COVID-19 and Cancer Consortium. Gulati S, et al. Among authors: shastri a. JAMA Oncol. 2023 Oct 1;9(10):1390-1400. doi: 10.1001/jamaoncol.2023.2934. JAMA Oncol. 2023. PMID: 37589970 Free PMC article.
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.
Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, Verma A, Feldman EJ, Goldfinger M. Levitz D, et al. Among authors: shastri a. Clin Cancer Res. 2023 Aug 1;29(15):2774-2780. doi: 10.1158/1078-0432.CCR-23-0842. Clin Cancer Res. 2023. PMID: 37341641
Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
Chai J, Choudhuri J, Wang Q, Fang Y, Shi Y, Kamel J, Shah N, Sica RA, Kornblum N, Konopleva M, Mantzaris I, Shastri A, Gritsman K, Verma A, Goldfinger M, Goel S, Wang Y, Tian X. Chai J, et al. Among authors: shastri a. Leuk Lymphoma. 2023 Oct;64(10):1662-1672. doi: 10.1080/10428194.2023.2232494. Epub 2023 Jul 10. Leuk Lymphoma. 2023. PMID: 37424335
Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort.
Hammami MB, Verceles JA, Goldfinger M, Shah N, Sica RA, Mantzaris I, Kornblum N, Konopleva M, Shastri A, Shapiro LC, Feldman EJ, Gritsman K, Verma A, Cooper DL. Hammami MB, et al. Among authors: shastri a. Transplant Cell Ther. 2024 May;30(5):544.e1-544.e8. doi: 10.1016/j.jtct.2024.02.020. Epub 2024 Feb 28. Transplant Cell Ther. 2024. PMID: 38417677
High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.
Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A. Goel S, et al. Among authors: shastri a. Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. Leukemia. 2016. PMID: 27125205 No abstract available.
STAT3 inhibition as a therapeutic strategy for leukemia.
Kanna R, Choudhary G, Ramachandra N, Steidl U, Verma A, Shastri A. Kanna R, et al. Among authors: shastri a. Leuk Lymphoma. 2018 Sep;59(9):2068-2074. doi: 10.1080/10428194.2017.1397668. Epub 2017 Nov 22. Leuk Lymphoma. 2018. PMID: 29164994 Review.
Therapeutic targeting of the inflammasome in myeloid malignancies.
Chakraborty S, Shapiro LC, de Oliveira S, Rivera-Pena B, Verma A, Shastri A. Chakraborty S, et al. Among authors: shastri a. Blood Cancer J. 2021 Sep 14;11(9):152. doi: 10.1038/s41408-021-00547-8. Blood Cancer J. 2021. PMID: 34521810 Free PMC article. Review.
Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.
Gonzalez-Lugo JD, Kambhampati S, Yacoub A, Donnellan WB, Berdeja J, Bhagat P, Fehn K, Remy C, Jasra S, Kazemi M, Pradhan K, Kim M, Mantzaris I, Sica RA, Shah N, Goldfinger M, Kornblum N, Gritsman K, Braunschweig I, Steidl U, Will B, Shastri A, Verma A. Gonzalez-Lugo JD, et al. Among authors: shastri a. Clin Cancer Res. 2023 Jan 4;29(1):60-66. doi: 10.1158/1078-0432.CCR-22-1457. Clin Cancer Res. 2023. PMID: 36255372 Clinical Trial.
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review.
Vegivinti CTR, Keesari PR, Veeraballi S, Martins Maia CMP, Mehta AK, Lavu RR, Thakur RK, Tella SH, Patel R, Kakumani VK, Pulakurthi YS, Aluri S, Aggarwal RK, Ramachandra N, Zhao R, Sahu S, Shastri A, Verma A. Vegivinti CTR, et al. Among authors: shastri a. Exp Hematol Oncol. 2023 Jul 8;12(1):60. doi: 10.1186/s40164-023-00422-1. Exp Hematol Oncol. 2023. PMID: 37422676 Free PMC article. Review.
203 results